 Connection
Charles Edelstein to Angiotensin-Converting Enzyme Inhibitors
This is a "connection" page, showing publications Charles Edelstein has written about Angiotensin-Converting Enzyme Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.470 |
|
|
|
-
Yalavarthy R, Smith ML, Edelstein C. Acute kidney injury complicating minimal change disease: the case for careful use of diuretics and angiotensin-converting enzyme inhibitors. Nephrology (Carlton). 2007 Oct; 12(5):529-31.
Score: 0.241
-
Edelstein CL. Therapeutic interventions for autosomal dominant polycystic kidney disease. Nephrol News Issues. 2008 Mar; 22(3):25-6.
Score: 0.062
-
Zafar I, Tao Y, Falk S, McFann K, Schrier RW, Edelstein CL. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Am J Physiol Renal Physiol. 2007 Sep; 293(3):F854-9.
Score: 0.059
-
Ecder T, Edelstein CL, Fick-Brosnahan GM, Johnson AM, Chapman AB, Gabow PA, Schrier RW. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol. 2001 Mar-Apr; 21(2):98-103.
Score: 0.038
-
Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000 Mar; 35(3):427-32.
Score: 0.036
-
Ecder T, Edelstein CL, Chapman AB, Johnson AM, Tison L, Gill EA, Brosnahan GM, Schrier RW. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 1999 May; 14(5):1113-6.
Score: 0.034
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|